Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Open accessThe DOI matches its Crossref record; 142 of the 149 references it cites were found in a registry or an index.
Abstract
Approximately 25% of US adults are estimated to have hypertriglyceridemia (triglyceride [TG] level ≥150 mg/dL [≥1.7 mmol/L]). Elevated TG levels are associated with increased cardiovascular disease (CVD) risk, and severe hypertriglyceridemia (TG levels ≥500 mg/dL [≥5.6 mmol/L]) is a well-established risk factor for acute pancreatitis. Plasma TG levels correspond to the sum of the TG content in TG-rich lipoproteins (TRLs; ie, very low-density lipoproteins plus chylomicrons) and their remnants. There remains some uncertainty regarding the direct causal role of TRLs in the progression of atherosclerosis and CVD, with cardiovascular outcome studies of TG-lowering agents, to date, having produced inconsistent results. Although low-density lipoprotein cholesterol (LDL-C) remains the primary treatment target to reduce CVD risk, a number of large-scale epidemiological studies have shown that elevated TG levels are independently associated with increased incidence of cardiovascular events, even in patients treated effectively with statins. Genetic studies have further clarified the causal association between TRLs and CVD. Variants in several key genes involved in TRL metabolism are strongly associated with CVD risk, with the strength of a variant's effect on TG levels correlating with the magnitude of the variant's effect on CVD. TRLs are thought to contribute to the progression of atherosclerosis and CVD via a number of direct and indirect mechanisms. They directly contribute to intimal cholesterol deposition and are also involved in the activation and enhancement of several proinflammatory, proapoptotic, and procoagulant pathways. Evidence suggests that non-high-density lipoprotein cholesterol, the sum of the total cholesterol carried by atherogenic lipoproteins (including LDL, TRL, and TRL remnants), provides a better indication of CVD risk than LDL-C, particularly in patients with hypertriglyceridemia. This article aims to provide an overview of the available epidemiological, clinical, and genetic evidence relating to the atherogenicity of TRLs and their role in the progression of CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Proposed pathophysiology of triglyceride-rich lipoproteins in the progression of atherosclerosis. Note: Adapted by permission from Macmillan Publishers Ltd: [Nature Reviews Cardiology] Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol. 2013;10(11):648–661,126 Copyright © 2013. Abbreviations: LPL, lipoprotein lipase; TRL, triglyceride-rich lipoproteins; TRL-R, triglyceride-rich lipoprotein remnants.](https://figures.cochat.ai/paper-figures/0257c3040d4b4514b3d59741a7e289ea/triglyceride-rich-lipoproteins-as-a-causal-factor-for-cardiovascular-disease-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon entering the arterial intima, these remnants are selectively retained through binding to extracellular matrix proteoglycans, prolonging their residence time in the subendothelial space. This retention facilitates uptake by resident macrophages via scavenger receptors, without requiring the oxidative modification typical of LDL particles.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genetic studies and epidemiologic data increasingly implicate remnant lipoproteins as causal contributors to atherogenesis, providing a strong mechanistic and clinical rationale for targeted intervention [8–12].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“The elevated cholesterol content per remnant particle, compared to LDL, amplifies their contribution to lipid accumulation and foam cell formation, key early events in plaque development [17].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“It is also worth noting that LDL-C levels are ordinarily estimated by the Friedewald equation.(116) The Friedewald equation is inapplicable for patients with fasting TG .”
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812 · cited 1×
“The Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardio (GISSI)-Prevenzione Trial showed that in postMI patients, EPA and DHA significantly reduced the risk of reinfarction and death over a 3-year follow-up period.(97) Additionally, in the Japan EPA Lipid Intervention Study (JELIS), the addition o…”
BackgroundESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Cited by
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Multi-organ proteomic landscape of COVID-19 autopsies
Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.004 · Cited by 408
Hypertriglyceridaemia and risk of coronary artery disease
Reiner, Ž. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.31 · Cited by 387
Virani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341
Hypertriglyceridemia and atherosclerosis
Peng, J., Luo, F., Ruan, G., Peng, R., & Li, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0625-0 · Cited by 245
“Additionally, the severe hypertriglyceridemia mainly contains CM that leads to pancreatitis [43], and the hydrolysis of CM via LPL results in the production of free fatty acids and chylomicron remnants which can contribute to pancreatitis [44].”
BackgroundWolska, A., Dunbar, R. L., Freeman, L. A., Ueda, M., Amar, M. J., Sviridov, D. O., & Remaley, A. T. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.025 · Cited by 231
Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease
Chait, A., Ginsberg, H. N., Vaisar, T., Heinecke, J. W., Goldberg, I. J., & Bornfeldt, K. E. (2020) · Diabetes · doi:10.2337/dbi19-0007 · Cited by 229
“Thus, genes involved in TRL metabolism such as lipoprotein lipase (LPL) and genes that control LPL’s activity appear to strongly associate with CVD risk (14).”
BackgroundCardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism
Duntas, L. H., & Brenta, G. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00511 · Cited by 217
“RLPs increase intimal cholesterol deposition and activate several proinflammatory, proapoptotic and procoagulant pathways (35).”
BackgroundThe Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 192
Gaggini, M., Gorini, F., & Vassalle, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010075 · Cited by 163
Cesaro, A., Michele, G. D., Fimiani, F., Acerbo, V., Scherillo, G., Signore, G., Rotolo, F. P., Scialla, F., Raucci, G., Panico, D., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1187735 · Cited by 188
“part of residual CV risk is associated with abnormal triglyceride levels (TG)-rich lipoproteins (TGRLs), their remnants, or alterations in the number or function of HDL (high density lipoprotein) (89).”
BackgroundNatural approaches in metabolic syndrome management
Patti, A. M., Al-Rasadi, K., Giglio, R. V., Nikolic, D., Mannina, C., Castellino, G., Chianetta, R., Banach, M., Cicero, A. F., Lippi, G., et al. (2018) · Archives of Medical Science · doi:10.5114/aoms.2017.68717 · Cited by 139
“These studies should provide valuable information on the utility of omega-3 fatty acids in combination with statin therapy in high-risk patients with TG levels of 200–500 mg/dl [71].”
BackgroundSelf-citationWang, L., Lin, Q., Yang, T., Liang, Y., Nie, Y., Luo, Y., Shen, J., Fu, X., Tang, Y., & Luo, F. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b03230 · Cited by 131
Makover, M. E., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100371 · Cited by 156
Self-citationSingh, A. K., Chaube, B., Zhang, X., Sun, J., Citrin, K. M., Canfrán-Duque, A., Aryal, B., Rotllan, N., Varela, L., Lee, R. G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140989 · Cited by 115
“the uptake of TRL-remnants in hepatocytes to prevent the accumulation of atherogenic lipoproteins in atherosclerotic plaques (62).”
BackgroundLu, Y., Cui, X., Zhang, L., Wang, X., Xu, Y., Qin, Z., Liu, G., Wang, Q., Tian, K., Lim, K. S., et al. (2022) · Aging and Disease · doi:10.14336/ad.2021.0929 · Cited by 131
“hydrolyzes TRLs in plasma, producing VLDL remnants (including chylomicron remnants and IDL) and high concentrations of lipolytic products such as oxidized free fatty acids [30].”
BackgroundHighlighting Residual Atherosclerotic Cardiovascular Disease Risk
Matsuura, Y., Kanter, J. E., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311999 · Cited by 94
“Mechanisms whereby TRL remnants or genes that impair remnant removal promote major ASCVD events are still poorly understood but are believed to include increased trapping of remnants in the artery wall, increased remnant uptake by lesional macrophages, inflammatory and proapoptotic effects on lesional cells, and proco…”
Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
Baratta, F., Cocomello, N., Coronati, M., Ferro, D., Pastori, D., Angelico, F., & Ben, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054268 · Cited by 94
Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis
Lorey, M. B., Öörni, K., & Kovanen, P. T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.841545 · Cited by 96
“Importantly, the lipoprotein lipase -mediated hydrolytic modification of the TGRLs takes place not only in capillaries but also in atherosclerosis-susceptible arterial segments where it results in high local concentrations of lipolytic products, such as oxidized free fatty acids which jointly with the TGRLs cause a mu…”
BackgroundSascău, R. A., Clément, A., Radu, R., Prisacariu, C., & Stătescu, C. (2021) · Nutrients · doi:10.3390/nu13061774 · Cited by 84
“Various epidemiological population-based studies on statin-treated subjects nominated TGs, triglyceride-rich lipoproteins (namely, chylomicrons and very-low-density lipoprotein particles (VLDL)), and their remnants as major determinants of the substantial residual cardiovascular risk [6].”
BackgroundInfluentialToxicological Evaluation of Low Molecular Weight Fucoidan in Vitro and in Vivo
Hwang, P.-A., Yan, M.-D., Lin, H.-T., Li, K.-L., & Lin, Y.-C. (2016) · Marine Drugs · doi:10.3390/md14070121 · Cited by 72
Budoff, M., Brent Muhlestein, J., Le, V. T., May, H. T., Roy, S., & Nelson, J. R. (2018) · Clinical Cardiology · doi:10.1002/clc.22856 · Cited by 73
“Atherosclerosis is a multistep process ranging from endothelial dysfunction to plaque development, progression, and rupture, leading to thrombus formation and cardiovascular events.(2,3) EPA has been reported to have beneficial effects on multiple atherosclerosis processes including endothelial function, oxidative str…”
BackgroundTriglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 104
“Furthermore, TGRL and their lipolytic products activate platelet aggregation and clot formation by suppressing fibrinolysis and promoting the assembly of prothombinase complex, the expression of plasminogen activator inhibitor-1 and its antigen, and the endothelial expression of tissue factor (Gianturco and Bradley, 1…”
BackgroundInfluentialVella, C. A., Nelson, M. C., Unkart, J., Miljkovic, I., & Allison, M. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.002 · Cited by 79
“This finding is consistent with the literature [8,11] and is clinically relevant given the growing epidemiological evidence that indicates fasting triglyceride levels are strong and independent predictors of atherosclerotic cardiovascular disease and all-cause mortality [27,28].”
ResultGeneroso, G., Janovsky, C. C. P. S., & Bittencourt, M. S. (2019) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000468 · Cited by 69
Chapman, M. J., Zamorano, J. L., & Parhofer, K. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108172 · Cited by 67
Dyslipidemia in Pediatric Type 2 Diabetes Mellitus
Sunil, B., & Ashraf, A. P. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01336-6 · Cited by 79
Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
Fan, W., Philip, S., Granowitz, C., Toth, P. P., & Wong, N. D. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00170-x · Cited by 66
Self-citationNovel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity
Paredes, S., Fonseca, L., Ribeiro, L. V. P. T., Ramos, H., Oliveira, J. C., & Palma, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-48120-5 · Cited by 78
Drager, L. F., Tavoni, T. M., Silva, V. M., Santos, R. D., Pedrosa, R. P., Bortolotto, L. A., Vinagre, C. G. C., Polotsky, V. Y., Lorenzi‐Filho, G., & Maranhão, R. C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m083436 · Cited by 68
“TRLPs enhance intimal cholesterol deposition and lead to activation of proinflammatory pathways (31).”
BackgroundAngiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects
Lupo, M. G., & Ferri, N. (2018) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd5030039 · Cited by 63
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Lorenzatti, A. J., & Toth, P. P. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.06 · Cited by 72
Self-citationExploring apolipoprotein C-III: pathophysiological and pharmacological relevance
Packard, C. J., Pirillo, A., Tsimikas, S., Ference, B. A., & Catapano, A. L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvad177 · Cited by 61
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
Takahashi, S. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17004 · Cited by 63
Skuratovskaia, D., Vulf, M. A., Komar, A., Кириенкова, Е. В., & Litvinova, L. S. (2019) · Biomolecules · doi:10.3390/biom9060226 · Cited by 60
Hansson, P., Holven, K. B., Øyri, L. K. L., Brekke, H. K., Biong, A. S., Gjevestad, G. O., Raza, G. S., Herzig, K., Thoresen, M., & Ulven, S. M. (2018) · Journal of Nutrition · doi:10.1093/jn/nxy291 · Cited by 64
Wakagi, M., Nagayasu, H., Yamashita, Y., & Ashida, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102436 · Cited by 62
Casula, M., Olmastroni, E., Gazzotti, M., Galimberti, F., Zambon, A., & Catapano, A. L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105060 · Cited by 54
Mechanism of Hypercholesterolemia-Induced Atherosclerosis
Prasad, K., & Mishra, M. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2306212 · Cited by 77
“Triglycerides (TG) enhance the generation of ROS and secretion of TGF-β and IL-β [78,79].”
BackgroundChu, S. S., Nguyen, H. A., Zhang, J., Tabassum, S., & Cao, H. (2022) · Sensors · doi:10.3390/s22145200 · Cited by 62
Multia, E., Liangsupree, T., Jussila, M., Ruiz‐Jiménez, J., Kemell, M., & Riekkola, M. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01986 · Cited by 59
A-FABP in Metabolic Diseases and the Therapeutic Implications: An Update
Li, H., Wu, X., Xu, A., & Hoo, R. L. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179386 · Cited by 61
“Dyslipidemia includes increased low-density lipoproteins (LDLs), decreased highdensity lipoproteins (HDLs), and increased fasting and postprandial triglyceride (TG)-rich lipoproteins (very-low-density lipoproteins [VLDL] and chylomicrons) [86,87].”
BackgroundBermúdez-López, M., Forné, C., Amigó, N., Božić, M., Arroyo, D., del Pino, T. B., Alonso, N., Cambray, S., y Pino, M. D. D. P., Mauricio, D., et al. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1620206 · Cited by 62
Apolipoprotein C-II: the re-emergence of a forgotten factor
Wolska, A., Reimund, M., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000680 · Cited by 52
Ballantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., Braeckman, R. A., Stirtan, W. G., Soni, P. N., & Juliano, R. A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.005 · Cited by 52
“Overall, current evidence suggests that elevated remnant cholesterol levels are one of the causal factors of residual ischemic heart disease risk [3] and cardiovascular disease [11].”
BackgroundTriglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
Handelsman, Y., & Shapiro, M. D. (2016) · Endocrine Practice · doi:10.4158/ep161445.ra · Cited by 60
“Mechanisms by which triglyceride-rich lipoproteins may contribute to atherosclerosis have been recently reviewed and are shown in Figure 1 (3,4).”
Sarin, H. V., Lee, J. H., Jauhiainen, M., Joensuu, A., Borodulin, K., Männistö, S., Jin, Z., Terwilliger, J. D., Isola, V., Ahtiainen, J. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40107-6 · Cited by 67
New perspectives on CKD-induced dyslipidemia
Bermúdez-López, M., Arroyo, D., Betriu, À., Masana, L., Fernández, E., & Valdivielso, J. M. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1369961 · Cited by 54
“During these consecutive transformations, they accumulate cholesterol esters and their triglyceride content declines [22].”
BackgroundPrediction for cardiovascular diseases based on laboratory data: An analysis of random forest model
Su, X., Xu, Y., Tan, Z., Wang, X., Yang, P., Su, Y., Jiang, Y., Qin, S., & Shang, L. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23421 · Cited by 48
Sairyo, M., Kobayashi, T., Masuda, D., Kanno, K., Zhu, Y., Okada, T., Koseki, M., Ohama, T., Nishida, M., Sakata, Y., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.39693 · Cited by 47
Nagayama, D., Watanabe, Y., Saiki, A., Shirai, K., & Tatsuno, I. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.42291 · Cited by 46
Cartier, L.-J., Collins, C., Lagacé, M., & Douville, P. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.11.007 · Cited by 44
Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease
Kou, M., Ding, N., Ballew, S. H., Salameh, M. J., Martin, S. S., Selvin, E., Heiss, G., Ballantyne, C. M., Matsushita, K., & Hoogeveen, R. C. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315828 · Cited by 44
The Effect of Helicobacter pylori Eradication on Lipid Levels: A Meta-Analysis
Watanabe, J., Hamasaki, M., & Kotani, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050904 · Cited by 46
Targeting the vasculature in cardiometabolic disease
Boutagy, N. E., Singh, A. K., & Sessa, W. C. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148556 · Cited by 46
“Conversely, during the fasting state, liver-derived apoB100-rich VLDL particles carry endogenous lipids to peripheral tissues (17).”
BackgroundDittrich, J., Beutner, F., Teren, A., Thiery, J., Burkhardt, R., Scholz, M., & Ceglarek, U. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.006 · Cited by 41
Olkkonen, V. M., Sinisalo, J. P., & Jauhiainen, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.019 · Cited by 43
Frers, R. A. K., Cosentino, V. L., Tau, J., Kerzberg, E. M., Urdapilleta, A., Chiocconi, M., Kogan, N. N., Losada, M. E. O., & Capani, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00139 · Cited by 42
“In previous studies, patients developed hypertriglyceridemia and showed an increase in the ApoB100/ ApoA1 ratio, both atherogenic and increasing cardiovascular risk (55).”
BackgroundCosta, D. N., Santosa, S., & Jensen, M. D. (2025) · Physiological Reviews · doi:10.1152/physrev.00008.2024 · Cited by 34
KONES, R. J., Howell, S. L., & Rumana, U. (2017) · Medical Principles and Practice · doi:10.1159/000485837 · Cited by 36
Chang, H., Sung, C., & Lin, M. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.08.082 · Cited by 37
Zafrir, B., Jubran, A., Hijazi, R., & Shapira, C. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.086 · Cited by 31
Srivastava, R. A. K. (2018) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-018-0378-y · Cited by 33
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320175 · Cited by 35
Godoy‐Matos, A. F., Valério, C. M., Júnior, W. S. D. S., Neto, J. M. D. A., Sposito, A. C., & Suassuna, J. H. R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01796-4 · Cited by 50
“…increased secretion and impaired clearance of TRL result in long exposure in the vessels, giving them a greater chance of crossing the vascular endothelium and being deposited in the form of plaques, triggering the inflammatory process that characteristically accompanies atherosclerosis [35, 36].”
Liu, T., Liu, J., Wu, Z., Lv, Y., & Li, W. (2021) · Clinical Cardiology · doi:10.1002/clc.23565 · Cited by 34
“Over a 27-year follow-up period, TG levels >5 mmol/L (440 mg/dl) and <1 mmol/L (88 mg/dl) were associated with 17- and 5-fold risks of myocardial infarction.(14) As the smallest and densest of the plasma lipoproteins, high-density lipoprotein (HDL) has been identified as a major recipient of free cholesterol and rever…”
BackgroundA new phenotypic classification system for dyslipidemias based on the standard lipid panel
Sampson, M. L., Ballout, R. A., Soffer, D. E., Wolska, A. T., Wilson, S. R., Meeusen, J. W., Donato, L. J., Fatica, E. M., Otvos, J. D., Brinton, E. A., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01585-8 · Cited by 37
“Although it is clear from genetic studies that many of the causes of hypertriglyceridemia increase the risk for ASCVD [61, 63, 64]; it is not known at this time if lowering TG will Sampson et al.”
BackgroundLópez-Toledano, M. A., Thorsteinsson, T., Daak, A. A., Maki, K. C., Johns, C., Rabinowicz, A. L., & Sancilio, F. D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.020 · Cited by 29
Golub, M., Lehofer, B., Martínez, N., Ollivier, J., Kohlbrecher, J., Prassl, R., & Peters, J. (2017) · Scientific Reports · doi:10.1038/srep46034 · Cited by 28
Triglyceride-Rich Lipoproteins as a Source of Proinflammatory Lipids in the Arterial Wall
Öörni, K., Lehti, S., Sjövall, P., & Kovanen, P. T. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180530094819 · Cited by 38
Bai, J., Yang, T., Zhou, Y., Xu, W., Han, S., Guo, T., Zhu, L., Qin, D., Luo, Y., Hu, Z., et al. (2022) · Foods · doi:10.3390/foods11111606 · Cited by 32
Drexel, H., Tamargo, J. L., Kaski, J. C., Lewis, B. S., Saely, C. H., Fraunberger, P., Dobrev, D., Komiyama, M., PLATTNER, T., Agewall, S., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad044 · Cited by 34
Traditional Chinese medicine for lipid metabolism disorders.
Li, Y., Wang, X., & Shen, Z. (2017) · Europe PMC (PubMed Central) · Cited by 34
Blood lipid markers are associated with hippocampal viscoelastic properties and memory in humans
Sanjana, F., Delgorio, P. L., Hiscox, L. V., DeConne, T. M., Hobson, J. C., Cohen, M. L., Johnson, C. L., & Martens, C. R. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20968032 · Cited by 33
Current Status of Primary, Secondary, and Tertiary Prevention of Coronary Artery Disease
Prasad, K. (2021) · International Journal of Angiology · doi:10.1055/s-0041-1731273 · Cited by 44
Pοlyzos, S. A., Bugianesi, E., Kountouras, J., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.08.001 · Cited by 30
“triglyceride levels are associated with increased CVD risk [26] and high LDL-C has now”
BackgroundOpportunities and options for surrogate assessment of insulin resistance
Ruyatkina, L. A., Ruyatkin, D. S., & Iskhakova, I. S. (2019) · Obesity and metabolism · doi:10.14341/omet10082 · Cited by 32
Yang, H. J., Xiao, L., & Xu, D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07001-0 · Cited by 26
Phospholipids in lipoproteins: compositional differences across VLDL, LDL, and HDL in pregnant women
Rauschert, S., Gázquez, A., Uhl, O., Kirchberg, F. F., Demmelmair, H., Ruíz‐Palacios, M., Prieto‐Sánchez, M. T., Blanco‐Carnero, J. E., Díaz, A. N., Larqué, E., et al. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-0957-z · Cited by 31
Ohtaki, S., Ashida, K., Matsuo, Y., Moritaka, K., Iwata, S., Nagayama, A., Kawaguchi, A., Koga, H., Yoshinobu, S., Hasuzawa, N., et al. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5671 · Cited by 21
Intuitive Eating and Biomarkers Related to Cardiovascular Disease in Older Adults
Teas, E., Kimiecik, J. C., Ward, R. M., & Timmerman, K. L. (2022) · Journal of Nutrition Education and Behavior · doi:10.1016/j.jneb.2022.01.010 · Cited by 28
Almond oil for patients with hyperlipidemia: A randomized open-label controlled clinical trial
Zibaeenezhad, M. J., Ostovan, P., Mosavat, S. H., Zamirian, M., & Attar, A. (2018) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2018.10.013 · Cited by 22
Liangsupree, T., Multia, E., Metso, J., Jauhiainen, M., Forssén, P., Fornstedt, T., Öörni, K., Podgornik, A., & Riekkola, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-47750-z · Cited by 22
Song, J., Huang, M., Shi, X., Li, X., Chen, X., He, Z., Li, J., Xu, G., & Zheng, J. (2021) · Animals · doi:10.3390/ani12010048 · Cited by 27
Bailetti, D., Bertoccini, L., Mancina, R. M., Barchetta, I., Capoccia, D., Cossu, E., Pujia, A., Lenzi, A., Leonetti, F., Cavallo, M. G., et al. (2019) · Obesity Science & Practice · doi:10.1002/osp4.311 · Cited by 19
“Because it is an inhibiting protein, loss-offunction (LoF) variants in ANGPTL4 such as E40K, act by enhancing adipose-specific LPL activity, resulting in lowering circulating TGs, a condition per se protective against cardiovascular disease (CVD) (11).”
BackgroundInfluentialJo, S. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.3.247 · Cited by 20
Soto, L. G. D. L. P., Gutierrez-Uribe, J. A., Sharma, A. K., & Ramírez‐Jiménez, A. K. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.035 · Cited by 19
Modder, M., Panhuis, W. I. H., Li, M., Afkir, S., Dorn, A. L., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., Pierrou, S. E., Nilsson, S. K., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae195 · Cited by 19
Lecamwasam, A., Mansell, T., Ekinci, E. I., Saffery, R., & Dwyer, K. M. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.821209 · Cited by 19
Comparison of metabolic and antioxidant responses to a breakfast meal with and without pecans
Marquardt, A. R., Lewandowski, K., Paton, C. M., & Cooper, J. A. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103559 · Cited by 17
Milonas, D., & Τζιόμαλος, Κ. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582028 · Cited by 17
Janovsky, C. C. P. S., Bittencourt, M. S., Goulart, A. C., Santos, R. D., Blaha, M. J., Jones, S. R., Toth, P. P., Lotufo, P. A., & Benseñor, I. M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa205 · Cited by 19
Self-citationBerta, E., Zsíros, N., Bodor, M., Balogh, I., Lőrincz, H., Paragh, G., & Harangi, M. (2022) · Genes · doi:10.3390/genes13071158 · Cited by 25
Elevated remnant cholesterol increase 6-year type 2 diabetes mellitus onset risk
Yuan, L., Liu, J., Huang, Z., Zhao, Y. W., Feng, Y., Yang, X., Hu, H., Zhang, J., Li, T.-Z., Li, Y., et al. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117253 · Cited by 18
Effects of the COVID-19 pandemic on the global health of women aged 50 to 70 years
de Lima, J. G. R., Abud, G. F., de Freitas, E. C., & Júnior, C. R. B. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111349 · Cited by 19
“Elevated levels of TG are known to increase the predisposition to cardiovascular diseases (Toth, 2016).”
Jayaraman, S., Baveghems, C. L., Chavez, O. R., Rivas-Urbina, A., Sánchez‐Quesada, J. L., & Gursky, O. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.03.001 · Cited by 17
“These findings are relevant to the established link between atherosclerosis and other pathologic conditions such as diabetes, metabolic syndrome, obesity and dyslipidemia [15-19,25-29], which are associated with elevated levels of TG, FFA and oxidation.”
BackgroundInfluentialAssociation between dairy product intake and hypertriglyceridemia in Korean adults
Park, S., Park, J., Song, H. J., Lee, C.-H., & Lee, H. (2020) · Nutrition Research and Practice · doi:10.4162/nrp.2020.14.2.152 · Cited by 16
“Low-density lipoprotein-cholesterol (LDL-C) regulation is a major consideration in CVD treatment, and hypertriglyceridemia is also considered a major target of CVD treatment [5-8].”
BackgroundToth, P. P., HULL, M. L., Granowitz, C. B., & Philip, S. (2020) · Future Cardiology · doi:10.2217/fca-2020-0123 · Cited by 16
Self-citation
Metadata
- Authors
- Toth, P.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Toth, Peter
- ORCID
- Toth, Peter
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2016-05
- Volume
- 12
- Pages
- 171
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- PMC
- PMC4866746
- OpenAlex
- W2345841042
- Cited by
- 237
- References
- 149
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 11 · 2023: 18 · 2022: 27 · 2021: 34 · 2020: 29 · 2019: 22 · 2018: 29 · 2017: 22 · 2016: 8
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vascular Health and Risk Management (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- triglyceride-rich lipoproteins, hypertriglyceridemia, cardiovascular risk, atherosclerosis, VLDL, chylomicrons, acute pancreatitis, non-HDL cholesterol, genetic variants, statin therapy, pro-inflammatory pathways, LDL cholesterol
- MeSH terms
- Animals, Hypolipidemic Agents, Cardiovascular Diseases, Humans, Lipoproteins, Phenotype, Risk Factors, Triglycerides, Hypertriglyceridemia, Biomarkers, Treatment Outcome, Disease Progression, Risk Assessment, Genetic Predisposition to Disease, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.